Carcinoma of Unknown Primary (CUP)
|
|
- Bernice Lesley French
- 6 years ago
- Views:
Transcription
1 Metasta c Carcinoma of Unknown Primary: Diagnos c Approach Using Immunohistochemistry James R. Conner, MD, PhD Mount Sinai Hospital Toronto, ON Carcinoma of Unknown Primary (CUP) 3-5% of all new malignant diagnoses 7 th or 8 th most common malignant tumor 4 th most common cause of tumor death Slowly declining incidence Improved diagnos c imaging Expanding repertoire of immunohistochemical markers 1
2 Roles of the Pathologist in CUP 1. Dis nguish carcinoma from melanoma, sarcoma, lymphoma 2. Define carcinoma subtype (adenocarcinoma, squamous cell carcinoma, hepatocellular carcinoma, etc) 3. Iden fy site of origin Immunohistochemistry in Workup of CUP Kera ns and their distribu on in carcinomas Lineage specific markers: Cytoplasmic proteins Lineage restricted transcrip on factors Iden fica on of primary liver tumors Squamous cell carcinomas Neuroendocrine tumors 2
3 High and Low Molecular Weight Kera ns LMWKs (CK8, CK18, CAM5.2) expressed by simple epithelium: Glandular epithelium Hepatocytes HMWKs (CK5, CK14, 34βE12) expressed by complex epithelium: Stra fied (squamous, transi onal) epithelium Some ductal epithelium Basal cells CK7 (KRT7) and CK20 (KRT20) Profile CK7+/CK20- CK7+/CK20+ CK7-/CK20+ CK7-/CK20- Most Frequent Primary Sites Breast, Mullerian, Lung, Thyroid Upper GI, Pancreas, Urothelial Colorectal, Merkel Cell Prostate, Hepatocellular, Renal, Adrenal 3
4 Lineage Restricted Markers Cytoplasmic (and Membranous) Markers Primary Site Markers (% Sensi vity) Breast Mammaglobin (60-80), GCDFP-15 (60-80) Lung Napsin A (60-80) Thyroid Thyroglobulin (80-90) Renal RCC (80-90 primary, metasta c) Hepatocellular HepPar1 (70-90), Arginase-1 (80-90) Prostate PSA (85-95), PSAP (85-95) Colorectal Villin (80-90) Adrenal Cortex MelanA/MART-1 (85-95), Inhibin (85-95) Bladder Uroplakin III (15-50), Uroplakin II (50-80) 4
5 Cytoplasmic (and Membranous) Markers In general, sensi vity is high in well-differen ated tumors but decreases substan ally in poorly differen ated tumors GCDFP-15 in Breast Carcinoma 5
6 Mammaglobin in Breast Carcinoma NapsinA in Pulmonary Adenocarcinoma 6
7 Remember Limita ons on Specificity Napsin A Ovarian clear cell carcinoma (80-100%) Papillary renal cell carcinoma (70-90%) Mammaglobin Endometrial carcinoma (10-30%) Inhibin, MelanA/MART-1 Sex cord stromal tumors (>80%) PSA Mammary carcinomas (20-40%) Salivary gland carcinomas (20-40%) Lineage Restricted Transcrip on Factors Expanding repertoire 15 years ago: TTF-1, CDX-2 Now: >50 markers for a wide spectrum of malignancies (NOT limited to carcinoma) Novel insights from developmental biology Essen al for organ specific development Implica on: Expression o en retained even in poorly differen ated tumors 7
8 Commonly Employed Markers in CUP Marker TTF-1 CDX-2 PAX8 GATA3 SATB2 OCT3/4 NKX3.1 SF1 Primary Sites Lung, Thyroid Colorectal, Appendix, Upper GI Mullerian, Kidney, Thyroid Breast, Bladder Colorectal Germ Cell Prostate Adrenal Cor cal, Sex Cord Stromal Poorly Differen ated (Insular) Thyroid Carcinoma TTF-1 PAX8 8
9 Poorly Differen ated Lung Adenocarcinoma TTF-1 PAX8 PAX8 in Ovarian Carcinoma 9
10 CDX-2 in Gastric Adenocarcinoma * Par cularly useful to exclude metasta c lobular breast carcinoma SATB2 in Colorectal Carcinoma 10
11 SATB2 and Osteoblas c Differen a on Dobreva G et al. Cell 2006 SATB2 in Osteosarcoma 11
12 GATA3 in Breast Carcinoma Mammaglobin GATA3 NKX3.1 in Prosta c Adenocarcinoma PSA NKX3.1 12
13 SF1 in Adrenal Cor cal Carcinoma Remember Primary Liver Tumors in the Differen al with CUP Hepatocellular Carcinoma Renal cell carcinoma Adrenal cor cal carcinoma Poorly differen ated carcinoma from any site Cholangiocarcinoma Pancrea c ductal adenocarcinoma Most other adenocarcinomas 13
14 HepPar-1 in Hepatocellular Carcinoma Cau on: HepPar-1 may react with gastric, esophageal, and lung adenocarcinomas, especially hepatoid variants 14
15 Arginase-1 in Hepatocellular Carcinoma Polyclonal CEA in Hepatocellular Carcinoma 15
16 Intrahepa c Cholangiocarcinoma No reliably specific marker O en CK7+, CK20+/-, CDX-2 weak, focal Approximately 50% with loss of SMAD4 Iden cal profile can be seen in metasta c pancrea c adenocarcinoma Dis nc ve Radiographic Features of Intrahape c Cholangiocarcinoma Heterogeneous and delayed enhancement Dilata on of intrahepa c bile ducts Capsular retrac on Satellite nodules Lobar atrophy 16
17 Intrahepa c Cholangiocarcinoma Bahe AD et al Squamous Cell Carcinoma Confirma on p63 (can be focally posi ve in up to 30% of lung adenocarcinomas) p40 (similar sensi vity, greater specificity) HMWKs (second line) Determina on of primary site rarely possible Excep on: virus associated tumors: EBV and nasopharyngeal carcinoma HPV and oropharyngeal carcinomas (tonsil/base of tongue) 17
18 Well Differen ated Neuroendocrine Tumors Increasingly important to determine primary site Pancrea c (but not midgut) NET effec vely treated with Streptozocin, Temozolomide, Everolimus, Suni nib Metasta c WD NETs Midgut (most common): CDX-2 Pancreas: PAX8 (polyclonal) Islet-1 Lung: TTF-1 18
19 ppax8 in Pancrea c WD NET Poorly Differen ated NEC Key: dis nguish visceral from cutaneous tumors Localized Merkel cell carcinoma will be treated surgically All other pa ents will receive pla num-based chemotherapy CK % of Merkel cell carcinomas Rare in other PDNECs TTF-1 Rare in Merkel cell carcinoma Common in PDNEC from most other sites 19
20 What is the site of origin? TTF-1 Key Points Assigning primary site in CUP improves outcomes Expect lower sensi vity in poorly differen ated tumors Lineage specific transcrip on factors increase sensi vity in most cases Knowledge of cross reac vity is cri cal to avoid misdiagnosis Remember to consider primary liver tumors 20
21 Select References Kandala P and Gown A. Arch Pathol Lab Med (2015) Epub ahead of print Conner J and Hornick J. Adv Anat Pathol (2015) 22(3): Bellizzi A. Adv Anat Pathol (2013) 20(5):
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY Jason L Hornick, MD, PhD Director of Surgical Pathology Director of Immunohistochemistry Brigham and Women s Hospital Associate
More informationCarcinoma of unknown primary origin (CUP) is defined
REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationImmunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationHistopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
More informationAdnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma?
Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma? skin Jane L. Messina, MD Interna0onal Melanoma Pathology Working Group 4 th annual mee0ng Tampa, Florida November 14, 2011
More informationReporting of carcinoma of unknown primary tumour (CUP)
Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationDiagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
More information8 years later! Next Generation Sequencing. Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_ ) (VAF: 59%) HNF1A Loss
8 years later! Next Generation Sequencing Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) (VAF: 59%) HNF1A Loss Interpretation HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) This
More informationThe unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
More informationList of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
More informationLiver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle
Liver Specialty Evening Conference Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle Case History A 65 year-old man presents with abdominal
More informationImmunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
More informationSupplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationBreast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
More informationNew Developments in Immunohistochemistry for Gynecologic Pathology
New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationFNA Cytology of Metastatic Malignancies of Unknown Primary Site
FNA Cytology of Metastatic Malignancies of Unknown Primary Site Tarik M. Elsheikh Jan F. Silverman Pathologic Diagnosis of Metastasis Smaller specimens, less invasive techniques FNA cytology is highly
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationCase 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
More informationNICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin)
CANCER OF UNKNOWN PRIMARY A Complex Disease NICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin) PROFESSOR OF MEDICAL ONCOLOGY Bogota, May-June 2016 WHAT IS CANCER OF UNKNOWN PRIMARY (CUP)? Is a clinical disorder where
More informationINTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS Gabor Fischer Diagnostic Services Manitoba University of Manitoba IHC INTERPRETATIONS LOCAL DATA Diagnostic Services Manitoba Number
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationDIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES
DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON Case 1 43 year-old female,
More informationNordic Immunohistochemical Quality Control
Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens
More informationExpression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Peiguo G. Chu, M.D., Ph.D., Lawrence M. Weiss, M.D. Department of Pathology, City of Hope National Medical Center,
More informationCase Hx. Mrs. CP 69 female non smoker Presented with 20 lb weight loss Some changes in bowel habit but no bleeding Upper abdominal discomfort PMH
Case Hx Mrs. CP 69 female non smoker Presented with 20 lb weight loss Some changes in bowel habit but no bleeding Upper abdominal discomfort PMH HTN, Dyslipidemia, GERD Breast reduction surgery Surgeries
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More information2/5/2014. BIOMARKERS AND PROSTATE CANCER Can new biomarkers improve clinical decision making? Samir Bidnur PGY Feb
BIOMARKERS AND PROSTATE CANCER Can new biomarkers improve clinical decision making? Samir Bidnur PGY- 3 5- Feb- 2013 Objec-ves Review the need for new biomarkers in prostate cancer management Discuss the
More informationWhat I Learned from 3 Cases and 3 Antibodies
What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships
More informationVideo Microscopy Tutorial 8
Video Microscopy Tutorial 8 Common and Uncommon Lesions of the Liver Gladwyn Leiman, MD There are no disclosures necessary. Common and Uncommon Lesions in Liver FNA Gladwyn Leiman University of Vermont
More informationReview and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes
More informationImportancia del patólogo en los tumores de origen desconocido
Importancia del patólogo en los tumores de origen desconocido Dr. Federico Rojo Fundación Jiménez Díaz, Madrid IMIM-Hospital del Mar, Barcelona Cancer unknown primary 3-5 % of diagnosed cancers Variability
More informationNICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin)
CANCER OF UNKNOWN PRIMARY A Complex Disease NICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin) EMERITUS PROFESSOR, UNIVERSITY OF IOANNINA DEAN, MEDICAL SCHOOL, UNIVERSITY OF CYPRUS ESO / ESMO MASTERCLASS, SAN JOSE,
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
More informationMalignant neoplasms of the gastrointestinal (GI) tract,
Special Section First Chinese American Pathologists Association Diagnostic Pathology Course, Part II Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary
More informationSection 14 Other Cancers. Cancer of Unknown 113 Primary Site INTRODUCTION PATHOLOGIC EVALUATION
Section 14 Other Cancers Cancer of Unknown 113 Primary Site F. Anthony Greco and John D. Hainsworth INTRODUCTION Cancer of unknown primary (CUP) site is a clinical syndrome that includes many types of
More informationZyto-Facts Editorial. News for Pathology and Immunohistochemistry. +++ Newsflash +++ Newsflash +++
Zyto-Facts 1-2016 News for Pathology and Immunohistochemistry Editorial The primary site of a tumor is not known in about 3 % to 5 % of all cancer diagnoses. Patients, whose primary site could be identified,
More informationSHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
More informationFNA Cytology of Metastatic Malignancies of Unknown Primary Site
FNA Cytology of Metastatic Malignancies of Unknown Primary Site Tarik M. Elsheikh Cleveland Clinic Jan F. Silverman Alleghany Hospitals Pathologic Diagnosis of Metastasis Smaller specimens, less invasive
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationIMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Update of mixed tumours of the GI tract, the pancreas and the liver Introduction to the concept of mixed tumours and clinical implication Jean-Yves SCOAZEC Surgical
More informationImmunoexpression of napsin a in renal neoplasms
Zhu et al. Diagnostic Pathology (2015) 10:4 DOI 10.1186/s13000-015-0242-z RESEARCH Open Access Immunoexpression of napsin a in renal neoplasms Bing Zhu, Stephen M Rohan and Xiaoqi Lin * Abstract Background:
More informationPATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. CANCER UNKNOWN PRIMARY 3-5 % of diagnosed cancers Variability
More informationInterventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationMesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
More informationISSN X (Print) Original Research Article. DOI: /sjams
DOI: 10.21276/sjams.2016.4.7.33 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(7C):2468-2473 Scholars Academic and Scientific Publisher (An International Publisher
More informationCase history: Figure 1. H&E, 5x. Figure 2. H&E, 20x.
1 Case history: A 49 year-old female presented with a 5 year history of chronic anal fissure. The patient s past medical history is otherwise unremarkable. On digital rectal examination there was a very
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
More informationUnknown Slides Conference
Unknown Slides Conference Jae Y. Ro, MD, PhD Weill Medical College of Cornell Univ. The Methodist Hospital, and UT MD Anderson Cancer Center Houston, TX November 9, 2013 Amman, Jordan 25 th Congress of
More informationImmunohistochemistry and Gastrointestinal Carcinomas
Cell Marque Tissue Diagnostics Immunohistochemistry and Gastrointestinal Carcinomas Mike Lacey, M.D. Gastrointestinal (GI) Pathology The life science business of Merck KGaA, Darmstadt, Germany operates
More informationCASE year old male with a PET avid nodule in the left adrenal gland
CASE 1 55 year old male with a PET avid nodule in the left adrenal gland Case 1 Adrenal gland parenchyma partly replaced by a spindle cell tumour with mild nuclear pleomorphism Atypical mitoses present
More informationFINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
More informationSerous effusion Objectives. Cytology of Serous Effusions From basics to challenges
Cytology of Serous Effusions From basics to challenges Cytology of Serous Effusions From basics to challenges Pınar Fırat, MD, MIAC Department of Pathology, İstanbul University, İstanbul Faculty of Medicine,
More informationGross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
More informationOriginal Article The clinicopathological features of metastatic tumors of the bladder: analysis of 25 cases
Int J Clin Exp Pathol 2018;11(12):5581-5591 www.ijcep.com /ISSN:1936-2625/IJCEP0087904 Original Article The clinicopathological features of metastatic tumors of the bladder: analysis of 25 cases Luhua
More informationCASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities
Female 31 CASE 4 LLETZ for borderline nuclear abnormalities PSA Ectopic Prostatic Tissue in Cervix AJSP 2006;30;209-215 usually incidental microscopic finding usually in ectocervical stroma? developmental
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationUropathology January Jon Oxley
Uropathology January 2012 Jon Oxley Background to seminar These slides were available to view via the web from scanned slides The junior pathologists answered questions on them via the web The answers
More information2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationCharles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationOutline. Hepatocellular Carcinoma Histologic variants. HCC: Histologic variants
2018 Park City AP Update Hepatocellular Carcinoma Histologic variants Sanjay Kakar, MD University of California, San Francisco Outline Histologic variants of HCC Morphologic and Immunohistochemical pitfalls
More informationMetastatic cancers can be difficult to diagnose in a. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2
CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2 David Altree-Tacha, PhD; Jillian Tyrrell, PhD; Thomas Haas, DO Context. CDH17, which is expressed in the intestinal epithelium,
More informationincidence rate x 100,000/year
Tier R=rare C=common Cancer Entity European crude and age adjusted incidence by cancer, years of diagnosis 2000 and 2007 Analisys based on 83 population-based cancer registries * applying the European
More informationLung Tumor Cases: Common Problems and Helpful Hints
Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists
More informationTechnology from Abcam
CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen
More informationNeuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:
H&N Neuroendocrine Neoplasms: Classification and Diagnostic Considerations Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Broad Classification: A. Epithelial:
More informationPOORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?
POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT? AGGRESSIVE THYROID CANCERS PAPILLARY CARCINOMA CERTAIN SUBTYPES POORLY DIFFERENTIATED CARCINOMA HIGH GRADE DIFFERENTIATED
More informationFINALIZED SEER SINQ QUESTIONS
20150007 MP/H Rules/Histology: What is the proper histology code -- mucin producing adenocarcinoma or cholangiocarcinoma for the following case? See discussion. Discussion 4/10/13 Partial hepatectomy:
More informationThermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring
Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays Excellent precision Confident cancer monitoring Thermo Scientific B R A H M S Biomarkers Tumor Markers Parameter Clinical Interest Product Technology
More informationIHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
More information- Selected Tumors of the Skin Appendages - Primary vs. Metastasis
- Selected Tumors of the Skin Appendages - Primary vs. Metastasis Napa Valley 2018 Victor G. Prieto, MD, PhD Chair of Pathology UT MD Anderson Cancer Center vprieto@mdanderson.org Napa Valley in May Introduction
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Laboratory Contact: Breege Nicholson Queen Elizabeth Hospital Tel: +44 (0) 208 333 3000 ext. 8478 Stadium Road E-Mail:
More informationNeuroendocrine tumors of GI and Pancreatobiliary tracts. N. Volkan Adsay, MD
Neuroendocrine tumors of GI and Pancreatobiliary tracts N. Volkan Adsay, MD New (2017) WHO WHO 2017 (endocrine book; for pancreas) WHO 2017 (endocrine book; for pancreas) PD-NE ca WD-NE Tumor Intended
More informationTumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director
Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28
More informationTissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2
Anatomic Pathology / CDH17 in Gastrointestinal Carcinomas Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2 Nicole C. Panarelli, MD,
More informationFURTHER WORK-UP. Ultrasound FNA or core needle biopsy (preferred) CT head and neck Consider PET/CT
EVALUATION History and physical including pelvic and/or rectal exam Hemoccult test CBC, LFTs, comprehensive metabolic profile, prostate specific antigen (PSA), other directed serum tumor markers CT chest,
More information